After Nutley Closure, Roche Picks NYC For East Coast R&D Site

Just months after announcing it would close its storied Nutley, N.J., R&D site, Roche said today that it will open a translational clinical research center at New York City’s Alexandria Life Sciences Center. The move means three big pharma firms will soon be enjoying a view of the East River: Lilly was the flagship tenant when two years ago it moved some 140 scientists from ImClone’s lower Manhattan labs into the sparkling new site. Pfizer later chose the Alexandria center for the New York hub of its Centers for Therapeutic Innovation, a unit that teams Pfizer scientists with academic scientists.

When Roche said it was shutting down the Nutley site, it said it was in search of an East Coast location for a much smaller research footprint. Some had initially speculated that Cambridge, Mass., would be the obvious choice for Roche, as most pharma companies have shifted their main East Coast R&D to the Boston area. More recently, it emerged that Roche was deciding between two locations in NY and N.J. Today’s release indicates that Roche plans to stick around N.Y. for awhile: it has signed an 11-year lease at the Alexandria Center.

Does this mean NYC, which has long struggled to attract pharma and biotech researchers to its fair streets, is starting to see some momentum in the life sciences?

Author: Lisa Jarvis

Share This Post On